Ribonucleoside Diphosphate Adducts with Elliptinium Acetate, an Antitumor Agent

Abstract

The oxidized form of the antitumor agent elliptinium acetate is able to arylate adenosine and uridine 5′-diphosphate by attack of the 2′-0 position of the ribose and cyclisation, leading to spiro derivatives. Ring opening occurs under reducing conditions and leads to the formation of adducts at 2′ or 3′ positions. Spiro and uncyclised adducts showed low cytotoxicity against L1210 cells in vitro.